Last reviewed · How we verify

Vyleesi (Autoinjector) — Competitive Intelligence Brief

Vyleesi (Autoinjector) (BREMELANOTIDE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Melanocortin Receptor Agonist. Area: Neuroscience.

marketed Melanocortin Receptor Agonist MC1R, MC4R Neuroscience Recombinant protein Live · refreshed every 30 min

Target snapshot

Vyleesi (Autoinjector) (BREMELANOTIDE) — Cosette. Bremelanotide activates melanocortin receptors, primarily MC1R and MC4R, to potentially improve HSDD, though the exact mechanism is unknown.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vyleesi (Autoinjector) TARGET BREMELANOTIDE Cosette marketed Melanocortin Receptor Agonist MC1R, MC4R 2019-01-01
Afamelanotide and NB-UVB Light Afamelanotide and NB-UVB Light Clinuvel, Inc. phase 3 Melanocortin receptor agonist Melanocortin-1 receptor (MC1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Melanocortin Receptor Agonist class)

  1. Cosette · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyleesi (Autoinjector) — Competitive Intelligence Brief. https://druglandscape.com/ci/bremelanotide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: